In the latest example of the life science sector's appeal to alt players, T-cell therapy specialist Neogene Therapeutics raised $110 million in a Series A round co-led by private equity firms Jeito Capital and Ecor1 Capital, along with British healthcare trust Syncona.
Neogene's research, which is still in the preclinical stage, aims to identify neoantigen specific T-cell receptor genes that will subsequently be engineered T cell therapies for solid tumors. T cell treatments are part of the cancer immunotherapy . . .
Unlock this article instantly, along with the rest of our premium content and daily, weekly and monthly newsletters. We offer pay-as-you-go monthly subscriptions and discounted annual subscriptions with additional benefits: access to Alternatives Watch Research articles and our Annual Investor Compendium.